The National Institute for Health and Care Excellence (NICE) faced "difficult decisions" when it deemed a breast cancer drug which can extend sufferers lives by "up to six months" was too expensive, according to a health expert.
Dr Hilary Jones told Daybreak the £90,000 price tag per patient would have meant taking funds away from other vital services the NHS provides.
More top news
Labour is promising to reverse the Conservative policy of privatisation in the NHS which it claims is creating longer waiting times.
The Queen and senior members of the monarchy will attend services around the world to commemorate the centenary of the battle of Gallipoli.